Key result
4-factor prothrombin complex concentrate (4F-PCC) is non-inferior for hemostatic efficacy and superior for international normalized ratio correction compared to plasma for vitamin K antagonist reversal.
Why the study?
Does 4-factor prothrombin complex concentrate improve hemostatic efficacy and INR correction compared to plasma in patients requiring vitamin K antagonist reversal?
Does 4-factor prothrombin complex concentrate improve hemostatic efficacy and INR correction compared to plasma in patients requiring vitamin K antagonist reversal?
4-factor prothrombin complex concentrate provides an effective and safe alternative to plasma for the rapid reversal of vitamin K antagonists in patients with bleeding or needing emergency surgery.
Answers are grounded in this paper and cite their sources.
Supports 4F-PCC preference for VKA reversal; leaves open prospective confirmation in broader populations.
Vitamin K antagonists (VKAs) have been used for decades for the treatment and prophylaxis of thromboembolic events. Due to their wide range of therapeutic indications, they are the most prescribed oral anticoagulant worldwide. However, they are associated with bleeding complications due to their narrow therapeutic range, variability in individual dose responses and laboratory monitoring, and overdoses. Despite off-label use of 3-factor prothrombin complex concentrates and recombinant activated factor VII, until recently, vitamin K and plasma were the only recommended therapeutic options for reversing VKAs in the USA. In 2013, a 4-factor prothrombin complex concentrate (4F-PCC) was approved in the USA for VKA reversal in patients with bleeding or requiring emergency surgery and invasive procedure. Recent randomized controlled clinical trials have shown that 4F-PCC (Kcentra™) is non-inferior for hemostatic efficacy and superior for international normalized ratio correction as compared to plasma and has a similar safety profile.
No takes yet. Share an insight, caveat, or question.
Kinard et al. (2014) conducted a review in Vitamin K antagonist reversal in patients with bleeding or requiring emergency surgery. 4-factor prothrombin complex concentrate (4F-PCC) vs. Plasma was evaluated on Hemostatic efficacy and international normalized ratio correction. 4-factor prothrombin complex concentrate (4F-PCC) is non-inferior for hemostatic efficacy and superior for international normalized ratio correction compared to plasma for vitamin K antagonist reversal.
Synapse has enriched 10 related papers. Consider them for comparative context: